University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

HIV InSite
Home | Patient/Public | Audio | News | Links
transparent gif
transparent giftransparent gif
transparent giftransparent gif
transparent giftransparent gif
Home > Treatment > Charts & Tables > Renal Dosing
Dosing of Antiretroviral Drugs in Adults with Renal Insufficiency and Hemodialysis
transparent image
transparent image
transparent image
transparent image
Introduction
transparent image
transparent image
Tables
transparent image
transparent image
transparent imageNucleoside/Nucleotide Analogues
transparent image
transparent imageFixed-Dose Combinations
transparent image
transparent imageNonnucleoside Reverse Transcriptase Inhibitors
transparent image
transparent imageProtease Inhibitors
transparent image
transparent imageFusion Inhibitors
transparent image
transparent imageChemokine Coreceptor Antagonists
transparent image
transparent imageIntegrase Inhibitors
transparent image
transparent image
References
transparent image
Related Resources
transparent imageRenal Manifestations of HIV
transparent image
transparent image
transparent image
transparent image
Introduction
transparent image

Several nucleoside and nucleotide analogue reverse transcriptase inhibitors are excreted primarily through the kidney and must be dose adjusted in the setting of renal insufficiency or hemodialysis. Although there are few data on the pharmacokinetic properties of the nonnucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, chemokine coreceptor antagonists, or integrase inhibitors in patients with renal insufficiency, the pharmacokinetic profiles of these drugs suggest that renal function has minimal effect on drug elimination. These tables summarize antiretroviral drug dose recommendations for patients with impaired renal function.

For further information, see the Renal Manifestations of HIV Knowledge Base Chapter.

transparent image
Tables
transparent image
transparent image
Nucleoside/Nucleotide Analogues
transparent image
Drug Standard Dosage Dosing in Renal Insufficiency and Hemodialysis References
Abacavir 300 mg PO BID Dosage adjustment for renal insufficiency does not appear necessary Ziagen package insert 5/07 (1)
Didanosine (enteric-coated capsules) 250 mg to 400 mg PO QD, depending on wt ClCr (mL/min) Wt ≥60 kg Wt <60 kg Videx EC package insert 11/06 (2, 3)
≥60 400 mg QD 250 mg QD
30-59 200 mg QD 125 mg QD
10-29 125 mg QD 125 mg QD
<10 125 mg QD formulation not suitable
HD 125 mg QD formulation not suitable
Emtricitabine 200 mg PO QD ClCr (mL/min) Emtriva package insert 4/08
≥50 200 mg QD
30-49 200 mg Q 48 H
15-29 200 mg Q 72 H
<15 200 mg Q 96 H
HD 200 mg Q 96 H, give dosage after dialysis
Lamivudine 150 mg PO BID or 300 mg PO QD ClCr (mL/min) Epivir package insert 2/08 (4, 5, 6)
≥50 150 mg BID or 300 mg QD
30-49 150 mg QD
15-29 150 mg first dose, then 100 mg QD
5-14 150 mg first dose, then 50 mg QD
<5 50 mg first dose, then 25 mg QD
Stavudine 20 mg to 40 mg PO BID, depending on wt ClCr (mL/min) Wt ≥60 kg Wt <60 kg Zerit package insert 4/08 (7)
>50 40 mg BID 30 mg BID
26-50 20 mg BID 15 mg BID
10-25 20 mg QD 15 mg QD
HD 20 mg QD 15 mg QD
Tenofovir 300 mg PO QD Experience in patients with ClCr <60 mL/min is limited. Preliminary data suggest: Viread package insert 5/07 (8)
ClCr (mL/min)
≥50 300 mg QD
30-49 300 mg Q 48 H
10-29 300 mg twice weekly (ie, Q 3-4 days)
HD 300 mg QW
Zidovudine 300 mg PO BID ClCr (mL/min) Retrovir package insert 11/06 (9, 10, 11)
<15 100 mg Q 6-8 H
HD 100 mg TID
transparent image
Fixed-Dose Combinations
transparent image
Drug Standard Dosage Dosing in Renal Insufficiency and Hemodialysis References

Abbreviations: BID = 2 times daily; ClCr = creatinine clearance; H = hours; HD = hemodialysis; PO = by mouth; Q = every; QD = 1 time daily; QHS = at bedtime; QW = once a week; TID = 3 times daily; Wt = weight

Atripla (efavirenz/emtricitabine/ tenofovir) 1 tab PO QHS Substitute component drugs, adjusting dosage of each drug for ClCr Atripla package insert 2/08
Combivir (zidovudine/lamivudine) 1 tab PO BID Substitute component drugs, adjusting dosage of each drug for ClCr Combivir package insert 4/07
Epzicom or Kivexa (abacavir/lamivudine) 1 tab PO QD Substitute component drugs, adjusting dosage of each drug for ClCr Epzicom package insert 5/07
Trizivir (zidovudine/lamivudine/abacavir) 1 tab PO BID Substitute component drugs, adjusting dosage of each drug for ClCr Trizivir package insert 5/07
Truvada (emtricitabine/tenofovir) 1 tab PO QD ClCr (mL/min) Truvada package insert 5/07
≥50 1 tab QD
30-49 1 tab Q 48 H
<30 Substitute component drugs, adjusting dosage of each drug for ClCr
transparent image
Nonnucleoside Reverse Transcriptase Inhibitors
transparent image

delavirdine, efavirenz, nevirapine
Dosage adjustment for renal insufficiency does not appear necessary.

transparent image
Protease Inhibitors
transparent image

amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir
Dosage adjustment for renal insufficiency does not appear necessary. Atazanavir should not be used for patients who are receiving hemodialysis. Although atazanavir is not cleared by hemodialysis, patients on hemodialysis have substantially lower plasma atazanavir concentrations compared with controls.(12, 13)

transparent image
Fusion Inhibitors
transparent image

enfuvirtide
Dosage adjustment for renal insufficiency does not appear necessary.

transparent image
Chemokine Coreceptor Antagonists
transparent image

maraviroc
Dosage adjustment for renal insufficiency does not appear necessary.

transparent image
Integrase Inhibitors
transparent image

raltegravir
Dosage adjustment for renal insufficiency does not appear necessary.

transparent image
transparent image
References
transparent image
1.   Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron 2001; 89:62-7.
transparent image
2.   Singlas E, Taburet AM, Borsa Lebas F, Parent de Curzon O, Sobel A, Chauveau P, Viron B, al Khayat R, Poignet JL, Mignon F, et al. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrob Agents Chemother 1992; 36:1519-24.
transparent image
3.   Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1996; 60:535-42.
transparent image
4.   Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002; 46:2387-92.
transparent image
5.   Izzedine H, Launay-Vacher V, Deray G. Dosage of lamivudine in a haemodialysis patient. Nephron 2000; 86:553.
transparent image
6.   Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, De Broe ME. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998; 46:21-7.
transparent image
7.   Grasela DM, Stoltz RR, Barry M, Bone M, Mangold B, O'Grady P, Raymond R, Haworth SJ. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis. Antimicrob Agents Chemother 2000; 44:2149-53.
transparent image
8.  Personal communication with J. Flaherty. 2002.
transparent image
9.   Kimmel PL, Lew SQ, Umana WO, Li PP, Gordon AM, Straw J. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease. Blood Purif 1995; 13:340-6.
transparent image
10.   Pachon J, Cisneros JM, Castillo JR, Garcia-Pesquera F, Canas E, Viciana P. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. Aids 1992; 6:827-30.
transparent image
11.   Tartaglione TA, Holeman E, Opheim K, Smith T, Collier AC. Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1990; 3:32-4.
transparent image
12.  Reyataz [patient information]. Princeton, NJ: Bristol-Myers Squibb; December 2007. Available at http://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed April 4, 2008.
transparent image
13.  Agarwala S et al. Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. In: Program and abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy. April 16-18, 2007; Budapest. Abstract 2.
transparent image
transparent image
transparent gif
transparent gif
grey line
About|Site Map|Feedback|Subscribe|Sponsors|Donate|Disclaimer
transparent gif
UCSF - Center for HIV Information

HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2008, Regents of the University of California.